Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple MyNewly diagnosed multiple myeloma, daratumumab, autologous stem cell transplanteloma (NDMM): Final Analysis of GRIFFIN
- Citation:
- OAB-057
- Meeting Instance:
- IMS 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- AFT
- Endpoint:
- No-Endpoint
- Analysis:
- Other
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Janssen
- Grants:
- Corr. Author:
- Authors:
- Douglas W. Sborov Jacob Laubach Jonathan L. Kaufman Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr. Nitya Nathwani Nina Shah Naresh Bumma Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Huiling Pei Annelore Cortoos Sharmila Patel Thomas S. Lin Paul Richardson Saad Z. Usmani Peter M. Voorhees
- Networks:
- CA043, CA136, CA249, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, OR013
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Newly diagnosed multiple myeloma, daratumumab, autologous stem cell transplant